1789.HK
AK Medical Holdings Limited [1789.HK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
1789.HK Stock Summary
Top 10 Correlated Stocks
1789.HK
In the News
1789.HK Financial details
Company Rating
Buy
Market Cap
5.95B
Income
443.98M
Revenue
2.44B
Book val./share
-
Cash/share
-
Dividend
0.06
Dividend %
1.07%
Employees
1.05K
Optionable
No
Shortable
Yes
Earnings
27 Mar 2024
P/E
27.8
Forward P/E
-
PEG
0.7
P/S
5.44
P/B
2.54
P/C
-
P/FCF
47.23
Quick Ratio
2.39
Current Ratio
4.73
Debt / Equity
-
LT Debt / Equity
0.02
-
-
EPS (TTM)
0.4
EPS next Y
-
EPS next Q
-
EPS this Y
125%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
5.15%
Revenue last 5Y
11.87%
Revenue Q/Q
-34.44%
EPS Q/Q
-63.23%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-28.57%
Inst Own
-
Inst Trans
-
ROA
7%
ROE
10%
ROC
0.09%
Gross Margin
60%
Oper. Margin
21%
Profit Margin
19%
Payout
12%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.89-11.18
52W High
-53%
52W Low
+72.33%
RSI
52
Rel Volume
0.51
Avg Volume
3.98M
Volume
2.04M
Perf Week
-4.44%
Perf Month
0%
Perf Quarter
-24.3%
Perf Half Y
-16.07%
-
-
-
-
Beta
-0.77
-
-
Volatility
0.09%, 0.21%
Prev Close
0.78%
Price
5.17
Change
2.17%
1789.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.58 | 0.89 | 0.94 | 0.68 | 0.95 | |
| Net income per share | 0.14 | 0.26 | 0.28 | 0.08 | 0.18 | |
| Operating cash flow per share | 0.12 | 0.14 | 0.19 | 0.16 | 0.22 | |
| Free cash flow per share | 0.05 | 0.04 | 0.1 | 0.09 | 0.11 | |
| Cash per share | 0.44 | 0.47 | 0.82 | 0.76 | 0.94 | |
| Book value per share | 0.81 | 1.07 | 1.85 | 1.83 | 2.02 | |
| Tangible book value per share | 0.75 | 0.99 | 1.64 | 1.62 | 1.78 | |
| Share holders equity per share | 0.81 | 1.07 | 1.85 | 1.83 | 2.02 | |
| Interest debt per share | 0 | 0.01 | 0.03 | 0.04 | 0.04 | |
| Market cap | 3.95B | 8.17B | 12.3B | 5.99B | 9.59B | |
| Enterprise value | 3.53B | 7.9B | 11.61B | 5.56B | 9B | |
| P/E ratio | 27.25 | 30.58 | 39.17 | 64.72 | 46.83 | |
| Price to sales ratio | 6.58 | 8.81 | 11.88 | 7.87 | 9.12 | |
| POCF ratio | 30.86 | 56.45 | 59.92 | 33.94 | 39.48 | |
| PFCF ratio | 72.53 | 216.34 | 106.51 | 59.71 | 79.12 | |
| P/B Ratio | 4.69 | 7.32 | 6.02 | 2.95 | 4.27 | |
| PTB ratio | 4.69 | 7.32 | 6.02 | 2.95 | 4.27 | |
| EV to sales | 5.88 | 8.53 | 11.22 | 7.3 | 8.56 | |
| Enterprise value over EBITDA | 18.39 | 23.14 | 26.49 | 30.17 | 27.88 | |
| EV to operating cash flow | 27.58 | 54.62 | 56.57 | 31.48 | 37.06 | |
| EV to free cash flow | 64.81 | 209.33 | 100.57 | 55.39 | 74.28 | |
| Earnings yield | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 | |
| Free cash flow yield | 0.01 | 0 | 0.01 | 0.02 | 0.01 | |
| Debt to equity | 0 | 0.01 | 0.01 | 0.02 | 0.02 | |
| Debt to assets | 0 | 0.01 | 0.01 | 0.02 | 0.01 | |
| Net debt to EBITDA | -2.19 | -0.78 | -1.57 | -2.35 | -1.82 | |
| Current ratio | 3.61 | 3.41 | 4.55 | 3.95 | 4.73 | |
| Interest coverage | -52.32 | 475.18 | 287.55 | 61.8 | 101.19 | |
| Income quality | 0.73 | 0.45 | 0.55 | 1.63 | 1.01 | |
| Dividend Yield | 0.01 | 0 | 0.01 | 0.01 | 0 | |
| Payout ratio | 0.22 | 0.12 | 0.24 | 0.4 | 0.12 | |
| Sales general and administrative to revenue | 0.12 | 0.1 | 0.08 | 0.14 | 0.11 | |
| Research and developement to revenue | 0.08 | 0.09 | 0.1 | 0.15 | 0.11 | |
| Intangibles to total assets | 0.06 | 0.06 | 0.09 | 0.09 | 0.1 | |
| Capex to operating cash flow | -0.57 | -0.74 | -0.44 | -0.43 | -0.5 | |
| Capex to revenue | -0.12 | -0.12 | -0.09 | -0.1 | -0.12 | |
| Capex to depreciation | -3.55 | -3.32 | -1.48 | -1.03 | -1.51 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0 | 0 | 0.01 | |
| Graham number | 1.6 | 2.49 | 3.45 | 1.85 | 2.9 | |
| ROIC | 0.17 | 0.23 | 0.15 | 0.04 | 0.08 | |
| Return on tangible assets | 0.14 | 0.19 | 0.14 | 0.04 | 0.08 | |
| Graham Net | 0.41 | 0.49 | 0.92 | 0.79 | 1.01 | |
| Working capital | 596.5M | 790.18M | 1.48B | 1.44B | 1.63B | |
| Tangible asset value | 775.78M | 1.03B | 1.81B | 1.8B | 1.98B | |
| Net current asset value | 573.95M | 751.84M | 1.42B | 1.36B | 1.53B | |
| Invested capital | 0 | 0.01 | 0.01 | 0.02 | 0.02 | |
| Average receivables | 152.7M | 270.06M | 454.2M | 541.47M | 537.9M | |
| Average payables | 49.46M | 67.44M | 112.39M | 119.27M | 123.97M | |
| Average inventory | 126.61M | 197.87M | 295.02M | 391.89M | 412.7M | |
| Days sales outstanding | 111.95 | 140.18 | 194.77 | 254.27 | 189.21 | |
| Days payables outstanding | 106.39 | 101.73 | 165.82 | 129.12 | 136.27 | |
| Days of inventory on hand | 316.86 | 295.31 | 410.34 | 588.82 | 353.34 | |
| Receivables turnover | 3.26 | 2.6 | 1.87 | 1.44 | 1.93 | |
| Payables turnover | 3.43 | 3.59 | 2.2 | 2.83 | 2.68 | |
| Inventory turnover | 1.15 | 1.24 | 0.89 | 0.62 | 1.03 | |
| ROE | 0.17 | 0.24 | 0.15 | 0.05 | 0.09 | |
| Capex per share | -0.07 | -0.1 | -0.08 | -0.07 | -0.11 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.58 | 0.53 | 0.66 | 0 | |
| Net income per share | 0 | 0.14 | 0.08 | 0.13 | 0 | |
| Operating cash flow per share | 0 | 0.19 | 0.03 | 0.01 | 0 | |
| Free cash flow per share | 0 | 0.13 | -0.01 | -0.09 | 0 | |
| Cash per share | 0 | 0.79 | 0.94 | 0.75 | 0 | |
| Book value per share | 0 | 1.93 | 2.02 | 2.11 | 0 | |
| Tangible book value per share | 0 | 1.73 | 1.78 | 1.94 | 0 | |
| Share holders equity per share | 0 | 1.93 | 2.02 | 2.11 | 0 | |
| Interest debt per share | 0 | 0.04 | 0.04 | 0.07 | 0 | |
| Market cap | 0 | 5.57B | 9.59B | 6.98B | 0 | |
| Enterprise value | -434.05M | 5.13B | 9B | 6.53B | 0 | |
| P/E ratio | 0 | 9.14 | 27.14 | 11.64 | 0 | |
| Price to sales ratio | 0 | 8.68 | 16.41 | 9.52 | 0 | |
| POCF ratio | 0 | 25.92 | 340.88 | 486.24 | 0 | |
| PFCF ratio | 0 | 38.87 | -619.34 | -70.71 | 0 | |
| P/B Ratio | 0 | 2.6 | 4.27 | 2.98 | 0 | |
| PTB ratio | 0 | 2.6 | 4.27 | 2.98 | 0 | |
| EV to sales | 0 | 7.99 | 15.4 | 8.9 | 0 | |
| Enterprise value over EBITDA | 0 | 24.86 | 58.66 | 30.87 | 0 | |
| EV to operating cash flow | -2.52 | 23.87 | 320.01 | 454.64 | 0 | |
| EV to free cash flow | -2.85 | 35.8 | -581.43 | -66.11 | 0 | |
| Earnings yield | 0 | 0.03 | 0.01 | 0.02 | 0 | |
| Free cash flow yield | 0 | 0.03 | 0 | -0.01 | 0 | |
| Debt to equity | 0.02 | 0.02 | 0.02 | 0.03 | 0 | |
| Debt to assets | 0.02 | 0.02 | 0.01 | 0.02 | 0 | |
| Net debt to EBITDA | 0 | -2.13 | -3.82 | -2.15 | 0 | |
| Current ratio | 3.95 | 4.66 | 4.73 | 3.33 | 0 | |
| Interest coverage | 0 | 112.85 | 95.08 | 165.12 | 0 | |
| Income quality | -9.11 | 1.7 | 0.36 | 0.11 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0.27 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0.1 | 0.11 | 0.1 | 0.16 | |
| Intangibles to total assets | 0.09 | 0.08 | 0.1 | 0.06 | 0 | |
| Capex to operating cash flow | -0.11 | -0.33 | -1.55 | -7.88 | 0 | |
| Capex to revenue | 0 | -0.11 | -0.07 | -0.15 | 0 | |
| Capex to depreciation | -0.56 | -1.75 | -1.16 | -2.55 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0.01 | 0 | 0 | |
| Graham number | 0 | 2.44 | 1.9 | 2.53 | 0 | |
| ROIC | 0 | 0.06 | 0.04 | 0.06 | 0 | |
| Return on tangible assets | 0 | 0.06 | 0.04 | 0.05 | 0 | |
| Graham Net | 0 | 0.8 | 1.01 | 0.78 | 0 | |
| Working capital | 1.44B | 1.53B | 1.63B | 1.49B | 0 | |
| Tangible asset value | 1.8B | 1.92B | 1.98B | 2.15B | 0 | |
| Net current asset value | 1.36B | 1.43B | 1.53B | 1.37B | 0 | |
| Invested capital | 0.02 | 0.02 | 0.02 | 0.03 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 65.68 | 83.98 | 85.75 | 0 | |
| Days payables outstanding | 0 | 35.59 | 54.46 | 89.41 | 0 | |
| Days of inventory on hand | 0 | 129.82 | 141.21 | 173.52 | 0 | |
| Receivables turnover | 0 | 1.37 | 1.07 | 1.05 | 0 | |
| Payables turnover | 0 | 2.53 | 1.65 | 1.01 | 0 | |
| Inventory turnover | 0 | 0.69 | 0.64 | 0.52 | 0 | |
| ROE | 0 | 0.07 | 0.04 | 0.06 | 0 | |
| Capex per share | 0 | -0.06 | -0.04 | -0.1 | 0 |
1789.HK Frequently Asked Questions
What is AK Medical Holdings Limited stock symbol ?
AK Medical Holdings Limited is a CN stock and trading under the symbol 1789.HK
What is AK Medical Holdings Limited stock quote today ?
AK Medical Holdings Limited stock price is $5.17 today.
Is AK Medical Holdings Limited stock public?
Yes, AK Medical Holdings Limited is a publicly traded company.
Company Profile
- Volume Average 3.98M
- Market Capitalization 5.95B
- Employee 1.05K
- CEO Mr. Zhijiang Li
- Headquarters Beijing,CN
- IPO Date 2017-12-20
-
Website
https://www.ak-medical.net 
AK Medical Holdings Limited, an investment holding company, designs, develops, produces, and markets orthopedic joint implants and related products under the AK Medical brand in China and internationally. It offers knee, hip, and spine replacement implants; and 3D-printed products, such as 3D-printed hip replacement implants, 3D-printed artificial vertebral bodies, and 3D-printed spinal interbody cages. The company also distributes third party orthopedic products; and manufactures surgical instruments and medical irrigators. Its principal customers include distributors, hospitals, physicians and surgeons, and patients. The company was founded in 2003 and is headquartered in Beijing, the People's Republic of China. AK Medical Holdings Limited is a subsidiary of Ximalaya Limited.
